Postdoctoral Research Scientist - Dr Payam Gammage

Mitochondrial Oncogenetics – Dr Payam Gammage (CRUK Beatson Institute)

&

Quantitative Cancer Metabolism Lab – Dr Ed Reznik (Memorial Sloan Kettering Cancer Center)

Investigating the metabolic impact and recurrence of mtDNA mutations in cancer

Salary Range: from £32,868 to £42,717 subject to experience, plus relocation allowance and visa costs if required.

Contract term: Fixed up to 6 years, subject to successful review at Year 3

About us

The CRUK Beatson Institute is a cancer research institute, situated in Glasgow with approximately 250 researchers split across 30 research groups consisting of PIs, postdoctoral scientists, PhD students and scientific officers. It is one of Europe's leading cancer research centres, supporting cutting-edge work into the molecular mechanisms of cancer development. As well as core support from Cancer Research UK, the Institute also receives an additional third of its total income from external grants and industry collaborations. It has an excellent reputation for fundamental cancer research, including world-class metabolism studies and renowned in vivo modelling of tumour growth and metastasis. Its research ethos is about excellence, honesty, openness, accountability, and integrity.

Project Outline

The majority of cancers bear mutations of the mitochondrial genome, and while our recent work has identified recurrence and selection of these mutations in tumours (Gorelick et al., 2021, Nature Metabolism) the function of these mutations in tumours is not yet established. In the Mitochondrial Oncogenetics Lab at CRUK BI, we have developed and applied advanced mitochondrial genome engineering techniques to create models of mitochondrial mutant cancer that we study in a variety of contexts.

Together with the Quantitative Cancer Metabolism Lab at Memorial Sloan Kettering Cancer Center, we aim to develop a broad understanding of the impact mtDNA mutations exert within and between tissue lineages, and this project will define the impact of recurrent mtDNA mutations in complex I genes on cancer metabolism and tumour growth across a range of in vitro and in vivo contexts. For a recent review of the field from our labs, see (Kim et al., 2022, Trends in Cancer).

Funded by a jointly held major award from the National Cancer Institute (NIH, USA) to establish a team split between the Gammage and Reznik labs at CRUK BI and MSKCC, this post will be primarily based at CRUK BI but with significant ongoing interaction with the US-based team, including bi-annual meetings in Glasgow and New York.

The successful applicant will be highly enthusiastic, driven to succeed and already have or soon be completing a PhD in mitochondrial or cancer biology and metabolism. Experience of mitochondrial genome engineering, cancer genomics or quantitative approaches to metabolic science are desirable but not essential.

Gorelick AN, et al., 2021, Respiratory complex and tissue lineage drive recurrent mutations in tumor mtDNA. Nature Metabolism. 3:558-570.

Kim M, et al., 2022, Mitochondrial DNA is a major source of driver mutations in cancer. Trends in Cancer. 8:1046-1059.

Postdoc support

Postdocs are key members of our research community, and we offer them a range of opportunities to train and develop as researchers while they are with us:

• Exciting, innovative cancer research projects in state-of-the art labs
• A highly collaborative and interactive research environment
• Access to and training in key advanced technologies, for example imaging and in vivo modelling
• A mentor enabling scheme to aid personal and professional development
• A rich programme of scientific exchange through seminars, workshops and meetings
• Support to make fellowship and small grant applications, including during their transition to their next position
• Guidance and mentoring to compete for an independent scientist position as well as a multitude of other career options, including in industry.
• A highly engaged postdoc forum, providing peer support, training, careers advice and regular social events

Equality, Diversity and Inclusion

Our overarching research ethos at the Institute is about excellence, honesty, openness, accountability and integrity. The diversity of our staff and students is also what makes the Institute such a vibrant place to work and advance discoveries in cancer research. Family friendly policies, our collaborative ethos, a focus on good mental health and well-being and opportunities for all help to create an enjoyable and inclusive workplace where your voice matters.

The Institute is also committed to increasing the number of female scientists at the postdoc level and beyond and encourages female applicants to apply. We have a highly attractive maternity policy which provides 12-18 months support and funding for postdocs wishing to take time off to spend with their children amongst other family friendly policies.

Employee Benefits

• Competitive salary
• 40.5 days annual leave including bank holidays (pro-rata)
• Defined Contribution pension scheme
• Life Insurance scheme
• Employee Assistance Programme
• Season ticket loan
• Additional maternity pay at 6 month’s full pay (subject to service)
• Shared parental leave
• Cycle to work scheme that could save you 26-40% on a bike and accessories.
• Access to Employee benefit schemes with discounts on supermarkets, cinema, travel and much more.
• On-site secure parking

 
Closing Date: Friday 14^th April 2023 but we may contact promising candidates on a rolling basis, so please apply as soon as you are ready.

APPLY HERE